Close Menu

NEW YORK (360Dx) – Volition America today announced it has signed an agreement to participate in a multicenter clinical cancer screening trial aimed at validating a panel of biomarkers for colorectal cancer.

Volition America, a wholly-owned subsidiary of VolitionRx, signed the deal to participate in the trial with Great Lakes New England Clinical Validation Center.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.